NASDAQ:ORMP Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free ORMP Stock Alerts $2.46 +0.16 (+6.96%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$2.31▼$2.4850-Day Range$2.20▼$3.5852-Week Range$1.67▼$5.25Volume84,471 shsAverage Volume164,756 shsMarket Capitalization$99.68 millionP/E Ratio17.57Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Oramed Pharmaceuticals alerts: Email Address Ad Stansberry ResearchMove Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. About Oramed Pharmaceuticals Stock (NASDAQ:ORMP)Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.Read More ORMP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ORMP Stock News HeadlinesMarch 16, 2024 | finance.yahoo.comORMP Apr 2024 2.500 putMarch 9, 2024 | finance.yahoo.comOramed Pharmaceuticals Full Year 2023 Earnings: Beats ExpectationsApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.February 21, 2024 | msn.comOramed to reinitiate pivotal type 2 diabetes trial after Phase III flopFebruary 20, 2024 | finanznachrichten.deOramed Pharmaceuticals Inc.: Oramed Letter to ShareholdersFebruary 20, 2024 | prnewswire.comOramed Letter to ShareholdersJanuary 24, 2024 | finance.yahoo.comORMP: Multiple Potential Applications for Proprietary Oral Protein Delivery PlatformNovember 28, 2023 | msn.comOramed Pharmaceuticals (ORMP) Price Target Increased by 36.51% to 4.39April 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.November 2, 2023 | msn.comOramed Pharmaceuticals (ORMP) Price Target Increased by 57.50% to 3.21October 6, 2023 | finance.yahoo.comOramed Pharmaceuticals (NASDAQ:ORMP) investors are sitting on a loss of 63% if they invested a year agoSeptember 21, 2023 | finance.yahoo.comOramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding CompanyAugust 2, 2023 | finance.yahoo.comOramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology GloballyJuly 25, 2023 | jp.reuters.comOramed Pharmaceuticals, Inc.June 20, 2023 | finance.yahoo.comOramed to Present at the 83rd American Diabetes Association ConferenceJune 17, 2023 | finance.yahoo.comOramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth PlansMay 30, 2023 | finance.yahoo.comORMP: Advancing Development Efforts in ChinaMay 24, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Hold Rating for Oramed Pharm (ORMP)May 18, 2023 | msn.comCanaccord Genuity Maintains Oramed Pharmaceuticals (ORMP) Hold RecommendationMay 18, 2023 | finance.yahoo.comOramed to Present at Novel Therapies for Type 2 Diabetes & Obesity SummitMay 16, 2023 | msn.comOramed Surges on New Diabetes TreatmentMay 15, 2023 | msn.comWhy Oramed Pharmaceuticals Shares Are Trading Higher TodayMay 15, 2023 | finance.yahoo.comOramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in ChinaMay 3, 2023 | msn.comInvesting millions, Ben Shapiro joins board of Oramed PharmaceuticalsMay 2, 2023 | marketwatch.com8-K: ORAMED PHARMACEUTICALS INC.May 2, 2023 | finance.yahoo.comConservative Pundit Ben Shapiro Invests $4.7 Million in Israeli Drug CompanyMay 1, 2023 | finance.yahoo.comOramed Appoints Ben Shapiro to its Board of DirectorsSee More Headlines Receive ORMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today4/26/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ORMP CUSIPN/A CIK1176309 Webwww.oramed.com Phone(844) 967-2633Fax972-2566-0004Employees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.14 Trailing P/E Ratio16.43 Forward P/E RatioN/A P/E GrowthN/ANet Income$5.53 million Net MarginsN/A Pretax Margin379.70% Return on Equity-7.15% Return on Assets-5.70% Debt Debt-to-Equity RatioN/A Current Ratio3.06 Quick Ratio3.06 Sales & Book Value Annual Sales$1.34 million Price / Sales69.55 Cash FlowN/A Price / Cash FlowN/A Book Value$4.04 per share Price / Book0.57Miscellaneous Outstanding Shares40,520,000Free Float35,657,000Market Cap$93.20 million OptionableOptionable Beta1.81 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Nadav Kidron Esq. (Age 50)President, CEO & Executive Chairman Comp: $754.3kMr. David Silberman CPA (Age 40)CFO & Treasurer Comp: $259.53kDr. Miriam Kidron Ph.D. (Age 84)Chief Scientific Officer & Director Comp: $503.95kMr. Joshua Hexter (Age 54)Chief Operating & Business Officer Comp: $326.94kKey CompetitorsIO BiotechNASDAQ:IOBTGeneluxNASDAQ:GNLXAbeona TherapeuticsNASDAQ:ABEOProPhase LabsNASDAQ:PRPHPMV PharmaceuticalsNASDAQ:PMVPView All CompetitorsInstitutional OwnershipAssenagon Asset Management S.A.Bought 18,659 shares on 4/24/2024Ownership: 0.046%BML Capital Management LLCSold 417,063 shares on 4/23/2024Ownership: 2.084%BML Capital Management LLCBought 480,267 shares on 1/30/2024Ownership: 3.127%View All Institutional Transactions ORMP Stock Analysis - Frequently Asked Questions How have ORMP shares performed in 2024? Oramed Pharmaceuticals' stock was trading at $2.31 on January 1st, 2024. Since then, ORMP shares have increased by 6.1% and is now trading at $2.45. View the best growth stocks for 2024 here. Are investors shorting Oramed Pharmaceuticals? Oramed Pharmaceuticals saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 367,600 shares, a decrease of 37.0% from the March 31st total of 583,900 shares. Based on an average daily volume of 168,800 shares, the short-interest ratio is presently 2.2 days. View Oramed Pharmaceuticals' Short Interest. When is Oramed Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ORMP earnings forecast. How were Oramed Pharmaceuticals' earnings last quarter? Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced its quarterly earnings data on Wednesday, March, 6th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.04. What other stocks do shareholders of Oramed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), DURECT (DRRX), OPKO Health (OPK), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN). Who are Oramed Pharmaceuticals' major shareholders? Oramed Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BML Capital Management LLC (2.08%) and Assenagon Asset Management S.A. (0.05%). Insiders that own company stock include Kevin Rakin, Michael Rabinowitz, Nadav Kidron and Yadin Rozov. View institutional ownership trends. How do I buy shares of Oramed Pharmaceuticals? Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ORMP) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
